John Jesitus

The TNF alpha inhibitor certolizumab pegol (Cimzia, UCB) has achieved the highest response rates seen in phase three trials of self-injectable biologics for psoriasis.

A meta-analysis of 43,643 patients with multiple sclerosis shows that these patients have an increased incidence and prevalence of psoriasis.

The patient-provider relationship in psoriasis care is plagued by various disconnects, a review shows. Decision aids, interdisciplinary involvement may help.

Halobetasol propionate once a week for eight weeks in plaque psoriasis patients was effective, with no adverse events.

It can take weeks to achieve results after restarting biologic treatments that were stopped, study shows.

Dermatologists must be able to distinguish between infected and noninfected diabetic foot ulcers because whether or not a DFU is infected can help determine treatment protocol, says Warrent S. Joseph, D.P.M, FIDSA. 

Patients with early-onset psoriasis are less likely than those with late-onset psoriasis to respond to systemic psoriasis treatments, a scientific review shows.

A review of more than 5,000 patients with moderate to severe plaque psoriasis who were treated with ixekizumab over three years, shows no unexpected safety signals.

Signs of aortic vascular inflammation in psoriasis patients may indicate early signs of coronary artery disease, report researchers writing in the Sept. 12 issue of JAMA Cardiology.

Psoriasis is associated with a host of comorbidities, such as obesity and the metabolic syndrome. In this study, researchers show that fatty liver disease is often the first sign of worsening health.

A novel tyrosine kinase 2 (TYK2) inhibitor may provide efficacy comparable to that of currently available biologic agents for psoriasis, without the adverse effects associated with JAK inhibitors, a study shows.

A recent review by the National Psoriasis Foundation's medical board suggests that adults with psoriasis and/or psoriatic arthritis (PsA) may use dietary interventions to supplement standard medical therapies to reduce disease severity.

Adalimumab trials in psoriasis show no new safety signals in nearly 5,500 patient-years (PYs) of exposure, shows a review in the British Journal of Dermatology.

When hurricanes Irma and Maria hit Puerto Rico in September 2017, the connections Dr. José Raúl Montes, an oculoplastic surgeon and frequent speaker at dermatology meetings, said that the connections he made through the years with peers and patients helped him stay afloat. Speaker and oculoplastic surgeon, José Raúl Montes, M.D., discusses how his love for music and passion for connection have lead him to train others on the proper use of injectables.

Biologic efficacy may not wane under previous exposure to biologic treatments, study shows.

A review of complementary and alternative medicines used by more than 51 percent of patients with psoriasis, shows that indigo naturalis, curcumin, dietary modification, fish oil, meditation, and acupuncture may be effective in some patients, but proceed cautiously investigators say.

Helping a dermatopathologist diagnose neoplasms and infections of the foot requires not only taking adequate samples, but in many cases, sending clinical photographs with them.

The new Thermage FLX adds speed and ease of use to the only monopolar radiofrequency (RF) device FDA-cleared for use on body and facial locations, including the eyelids, with a single treatment.

A JAMA Dermatology study shows that adherence to a Mediterranean diet high in anti-inflammatory nutrients may lessen psoriasis severity.

The prevalence of psoriatic arthritis in patients with psoriasis worldwide appears to be around 20 percent, shows a meta-analysis published in JAAD.

Patients with psoriasis have a higher risk of developing new onset diabetes mellitus. It’s a risk that’s been described as statistically significant. So, in this article, we examine dermatologic care for diabetic foot infections.

Many tools and strategies can help dermatologists overcome their discomfort in addressing psoriatic arthritis (PsA) in patients with psoriasis, physicians report.

Newer biologics that target interleukin (IL)-17 and IL-23 are changing the paradigm for psoriasis treatment, report physicians.

Here's a look at new botulinum toxin treatments on the horizon.

Ustekinumab has a higher drug survival rate than adalimumab, etanercept and infliximab, confirms a study of plaque psoriasis patients published in the Journal of Cutaneous Medicine and Surgery.

In inflammatory arthritis, the molecular and genetic makeup of synovial tissues appears to hold clues that one day may guide clinical decision-making. Re: EULAR report.

A new study advises selecting biologic therapies for psoriasis based on individual factors such as patients' comorbidities, preferences and clinical situation, as well as the advantages and disadvantages of particular biologic treatments.

This is the first time an IL-23 blocking drug has been shown to improve signs and symptoms of psoriatic arthritis.

Despite the popularity of fractional ablative resurfacing, full-field erbium resurfacing still has an important role in skin rejuvenation.

Efficacy and safety outcomes of clinical trials involving biologic psoriasis drugs overstate these drugs' real-world utility, shows a JAMA Dermatology study.